S&P 500   4,603.40 (-1.11%)
DOW   34,725.39 (-1.17%)
QQQ   394.17 (-1.38%)
AAPL   162.72 (+1.55%)
MSFT   333.11 (-1.05%)
FB   329.33 (-2.57%)
GOOGL   2,871.21 (-1.35%)
AMZN   3,518.61 (-1.21%)
TSLA   1,141.18 (+0.37%)
NVDA   323.27 (-3.14%)
BABA   127.12 (-3.41%)
NIO   39.40 (-2.62%)
CGC   10.60 (-4.16%)
AMD   158.93 (-1.84%)
GE   95.85 (-2.59%)
MU   85.20 (-1.09%)
T   22.81 (-4.52%)
F   19.42 (-1.27%)
DIS   144.57 (-2.19%)
ACB   6.31 (-2.02%)
AMC   34.67 (-5.89%)
PFE   53.35 (+1.81%)
BA   195.08 (-1.72%)
S&P 500   4,603.40 (-1.11%)
DOW   34,725.39 (-1.17%)
QQQ   394.17 (-1.38%)
AAPL   162.72 (+1.55%)
MSFT   333.11 (-1.05%)
FB   329.33 (-2.57%)
GOOGL   2,871.21 (-1.35%)
AMZN   3,518.61 (-1.21%)
TSLA   1,141.18 (+0.37%)
NVDA   323.27 (-3.14%)
BABA   127.12 (-3.41%)
NIO   39.40 (-2.62%)
CGC   10.60 (-4.16%)
AMD   158.93 (-1.84%)
GE   95.85 (-2.59%)
MU   85.20 (-1.09%)
T   22.81 (-4.52%)
F   19.42 (-1.27%)
DIS   144.57 (-2.19%)
ACB   6.31 (-2.02%)
AMC   34.67 (-5.89%)
PFE   53.35 (+1.81%)
BA   195.08 (-1.72%)
S&P 500   4,603.40 (-1.11%)
DOW   34,725.39 (-1.17%)
QQQ   394.17 (-1.38%)
AAPL   162.72 (+1.55%)
MSFT   333.11 (-1.05%)
FB   329.33 (-2.57%)
GOOGL   2,871.21 (-1.35%)
AMZN   3,518.61 (-1.21%)
TSLA   1,141.18 (+0.37%)
NVDA   323.27 (-3.14%)
BABA   127.12 (-3.41%)
NIO   39.40 (-2.62%)
CGC   10.60 (-4.16%)
AMD   158.93 (-1.84%)
GE   95.85 (-2.59%)
MU   85.20 (-1.09%)
T   22.81 (-4.52%)
F   19.42 (-1.27%)
DIS   144.57 (-2.19%)
ACB   6.31 (-2.02%)
AMC   34.67 (-5.89%)
PFE   53.35 (+1.81%)
BA   195.08 (-1.72%)
S&P 500   4,603.40 (-1.11%)
DOW   34,725.39 (-1.17%)
QQQ   394.17 (-1.38%)
AAPL   162.72 (+1.55%)
MSFT   333.11 (-1.05%)
FB   329.33 (-2.57%)
GOOGL   2,871.21 (-1.35%)
AMZN   3,518.61 (-1.21%)
TSLA   1,141.18 (+0.37%)
NVDA   323.27 (-3.14%)
BABA   127.12 (-3.41%)
NIO   39.40 (-2.62%)
CGC   10.60 (-4.16%)
AMD   158.93 (-1.84%)
GE   95.85 (-2.59%)
MU   85.20 (-1.09%)
T   22.81 (-4.52%)
F   19.42 (-1.27%)
DIS   144.57 (-2.19%)
ACB   6.31 (-2.02%)
AMC   34.67 (-5.89%)
PFE   53.35 (+1.81%)
BA   195.08 (-1.72%)
NASDAQ:VTYX

Ventyx Biosciences Stock Forecast, Price & News

$19.05
-1.28 (-6.30%)
(As of 11/30/2021 11:03 AM ET)
Add
Compare
Today's Range
$19.00
$20.29
50-Day Range
N/A
52-Week Range
$16.32
$26.00
Volume
1,071 shs
Average Volume
258,535 shs
Market Capitalization
$958.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive VTYX News and Ratings via Email

Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter.


Ventyx Biosciences logo

About Ventyx Biosciences

Ventyx Biosciences Inc. is a clinical-stage biopharmaceutical company. It focused on advancing new therapies for patients living with inflammatory diseases and autoimmune disorders. The company's clinical stage pipeline includes VTX958, VTX002 and VTX2735. Ventyx Biosciences Inc. is headquartered in Encinitas, California.

Headlines

Ventyx Biosciences (NASDAQ:VTYX) Stock Price Down 6.1%
November 29, 2021 |  americanbankingnews.com
Ventyx Biosciences (NASDAQ:VTYX) Shares Up 8.4%
November 26, 2021 |  americanbankingnews.com
Ventyx Biosciences (NASDAQ:VTYX) Shares Gap Down to $21.90
November 22, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Medicinal and Botanical Manufacturing
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTYX
Web
N/A
Phone
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$958.16 million
Optionable
Not Optionable

Company Calendar

Today
11/30/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

564th out of 1,390 stocks

Medicinal And Botanical Manufacturing Industry

1st out of 1 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Ventyx Biosciences (NASDAQ:VTYX) Frequently Asked Questions

Is Ventyx Biosciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ventyx Biosciences stock.
View analyst ratings for Ventyx Biosciences
or view top-rated stocks.

What price target have analysts set for VTYX?

4 equities research analysts have issued 12 month target prices for Ventyx Biosciences' shares. Their forecasts range from $30.00 to $50.00. On average, they anticipate Ventyx Biosciences' stock price to reach $43.33 in the next year. This suggests a possible upside of 118.5% from the stock's current price.
View analysts' price targets for Ventyx Biosciences
or view top-rated stocks among Wall Street analysts.

Who are some of Ventyx Biosciences' key competitors?

When did Ventyx Biosciences IPO?

(VTYX) raised $152 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 9,472,656 shares at $15.00-$17.00 per share.

What is Ventyx Biosciences' stock symbol?

Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX."

When did the company's quiet period expire?

Ventyx Biosciences' quiet period expired on Tuesday, November 30th. Ventyx Biosciences had issued 9,472,656 shares in its public offering on October 21st. The total size of the offering was $151,562,496 based on an initial share price of $16.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Ventyx Biosciences?

Shares of VTYX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ventyx Biosciences' stock price today?

One share of VTYX stock can currently be purchased for approximately $19.83.

How much money does Ventyx Biosciences make?

Ventyx Biosciences has a market capitalization of $997.39 million.


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.